Core Insights - Milestone Scientific Inc. has launched The Wand® Ambassador Program to enhance clinical awareness and adoption of The Wand® STA System in the dental market [1][6] Group 1: Program Overview - The Ambassador Program is a peer-to-peer initiative that utilizes experienced dental professionals to share clinical insights and experiences, aiming to foster engagement with potential practices [2] - The pilot of the program began on December 8 with six dental professionals in select U.S. markets, receiving positive feedback and interest from additional practitioners [3] Group 2: Expansion Plans - Milestone plans to scale the program to approximately 250 dental professionals within the next 12 months, supported by structured onboarding and educational resources [4] - The program includes tools for real-time visibility into engagement activities, allowing the company to measure effectiveness and optimize execution [4] Group 3: Expected Outcomes - Based on early pilot results, Milestone anticipates a 2-3x increase in product demonstrations, which will enhance demo-to-sales conversion efficiency [5] - The Ambassador Program is expected to strengthen market awareness and support broader adoption of The Wand STA system, contributing to sustainable growth [6] Group 4: Leadership Perspective - CEO Eric C. Hines expressed optimism regarding the early response to the program, highlighting its potential to increase product demonstrations and reinforce clinical confidence [7]

Financial Data and Key Metrics Changes - For Q3 2025, revenue was $2.4 million, a slight decrease from $2.5 million in Q3 2024. For the nine months ended September 30, 2025, revenue was $6.9 million, compared to $6.6 million for the same period in 2024 [10] - Gross profit for the nine months ended September 30, 2025, was approximately $4.9 million, reflecting no material year-over-year change [10] - Operating expenses were approximately $1.1 million for Q3 2025, down over $500,000 compared to the same period last year [5][10] Business Line Data and Key Metrics Changes - In the dental segment, international sales increased year-over-year, partially offsetting a decline in domestic revenue [7] - Utilization of CompuFlow disposables rebounded slightly, indicating a re-engagement with current customers [7] Market Data and Key Metrics Changes - The company has a market share of approximately 1.5%-2% in both domestic and international markets, indicating significant room for growth [16] Company Strategy and Development Direction - The company is focused on three strategic priorities: streamlining operations, strengthening commercial execution in dental and medical sectors, and advancing reimbursement strategies for CompuFlow [6][8] - The addition of Dr. Dawood Syed to the board aims to enhance clinical and payer expertise, supporting the strategy for broader adoption within hospital systems [8] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of disciplined execution and operational excellence to build value for shareholders and customers [12] - The company plans to focus on a handful of states for CompuFlow's rollout, ensuring proper data collection for Medicare reimbursement [21][22] Other Important Information - As of September 30, 2025, the company had cash and cash equivalents of approximately $1.3 million and working capital of approximately $3.1 million [11] Q&A Session Summary Question: How to convince dental clinics to invest in new equipment? - Management acknowledged the need to reconnect with old customers and expand digital marketing efforts to raise awareness about the benefits of their products [15][16] Question: Update on the medical side and broader commercialization plans? - The focus is on supporting current clinics using CompuFlow and collecting data for Medicare reimbursement, with plans for broader commercialization in the near future [21][22] Question: Impact of tariffs on supply chain and customer behavior? - Management reported minimal impact from tariffs and is considering a bonded warehouse in the U.S. to mitigate potential issues [29] Question: Structure of the salesforce and reimbursement specialists? - The company plans to ramp up the salesforce and is considering pursuing reimbursement codes for pediatric use [31] Question: Is there a seasonality pattern in sales? - Management indicated that the business is steady without significant seasonal fluctuations, expecting a similar performance in Q4 [32] Question: Future prospects and challenges for Milestone Scientific? - Management acknowledged past challenges but emphasized a focused approach with strong technology and a structured plan for growth [39][40] Question: Current cash position and capital needs? - The company has sufficient cash to operate for several quarters and is looking for opportunities to improve its financial position [47]

Financial Data and Key Metrics Changes - For Q3 2025, revenue was $2.4 million, a slight decrease from $2.5 million in Q3 2024. For the nine months ended September 30, 2025, revenue was $6.9 million, compared to $6.6 million for the same period in 2024 [10] - Operating expenses were reduced by over $500,000 compared to the same period last year, reflecting disciplined cost management [5][10] - As of September 30, 2025, cash and cash equivalents were approximately $1.3 million, with working capital of approximately $3.1 million [11] Business Line Data and Key Metrics Changes - In the dental segment, international sales increased year-over-year, partially offsetting a decline in domestic revenue [7] - Utilization of CompuFlow disposables rebounded slightly, indicating a re-engagement with current customers [7] Market Data and Key Metrics Changes - The company has a market share of approximately 1.5%-2% in both domestic and international markets, indicating significant room for growth [16] Company Strategy and Development Direction - The company is focused on three strategic priorities: streamlining operations, strengthening commercial execution in dental and medical sectors, and advancing reimbursement strategies for CompuFlow [6][12] - The addition of Dr. Dawood Syed to the board aims to enhance clinical and payer expertise, supporting the strategy for broader adoption within hospital systems [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's technology and the need for a structured approach to sales and reimbursement strategies [39][40] - The focus is on disciplined execution and operational excellence to build long-term shareholder value [12][50] Other Important Information - The company is enhancing its omnichannel marketing strategy to increase brand visibility and customer engagement [9] Q&A Session Summary Question: How to convince dental clinics to invest in new equipment? - Management acknowledged the need to reconnect with old customers and expand digital marketing efforts to raise awareness about the benefits of their products [15][16] Question: Update on the medical side and broader commercialization plans? - The company is focusing on a few jurisdictions for CompuFlow and plans to collect data meticulously to support Medicare reimbursement [21][22] Question: Impact of tariffs on supply chain and customer behavior? - Management reported minimal impact from tariffs and is considering a bonded warehouse in the U.S. to mitigate potential issues [29] Question: Structure of the salesforce and reimbursement specialists? - The company plans to ramp up its sales organization and is considering pursuing reimbursement codes for pediatric use [30][31] Question: Is there a seasonality pattern in sales? - Management indicated that the business is steady without significant seasonal fluctuations, expecting a similar performance in Q4 [32] Question: Long-term outlook and challenges faced? - Management emphasized the importance of having a structured approach to sales and reimbursement to ensure sustainable growth [39][40] Question: Current cash position and need for capital? - The company has sufficient cash to operate for several quarters and is looking for opportunities to improve its financial position [47]

Financial Data and Key Metrics Changes - For Q3 2025, revenue was $2.4 million, a slight decrease from $2.5 million in Q3 2024. For the nine months ended September 30, 2025, revenue was $6.9 million, compared to $6.6 million for the same period in 2024 [10] - Gross profit for the nine months ended September 30, 2025, was approximately $4.9 million, reflecting no material year-over-year change [10] - Operating expenses were approximately $1.1 million for Q3 2025, a reduction of over $500,000 compared to the same period last year [5][10] Business Line Data and Key Metrics Changes - In the dental segment, international sales increased year-over-year, partially offsetting a decline in domestic revenue [6] - Utilization of CompuFlow disposables rebounded slightly, indicating a re-engagement with current customers [6][8] Market Data and Key Metrics Changes - The company has a market share of approximately 1.5%-2% in both domestic and international markets, indicating significant room for growth [17] - The company is focusing on expanding its commercial coverage footprint in key jurisdictions like New Jersey, Texas, and Florida [8][24] Company Strategy and Development Direction - The company is executing a transformational strategy focused on streamlining operations, strengthening commercial execution, and advancing reimbursement strategies for CompuFlow [5][12] - The addition of Dr. Dawood Syed to the board aims to enhance clinical and payer expertise, supporting the strategy for broader adoption within hospital systems [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's technology and emphasized the need for a structured approach to sales and reimbursement to ensure sustainable growth [40][41] - The focus remains on disciplined execution, operational excellence, and building value for shareholders, customers, and patients [12][54] Other Important Information - As of September 30, 2025, the company had cash and cash equivalents of approximately $1.3 million and working capital of approximately $3.1 million [11] - The company is considering establishing a bonded warehouse in the U.S. to mitigate potential tariff impacts [29] Q&A Session Summary Question: How to convince dental clinics to invest in new equipment? - Management acknowledged the challenge and emphasized the need for better education and marketing to increase awareness of the product's benefits [15][17] Question: What is the plan for broader commercialization of CompuFlow? - The focus is on a few key states and jurisdictions, with plans to collect data meticulously to support Medicare reimbursement [21][22] Question: How is the salesforce structured? - The company plans to ramp up the salesforce and is considering adding reimbursement specialists to enhance sales efforts [31][32] Question: Is there a seasonality pattern in sales? - Management indicated that the business is steady without significant seasonal fluctuations, expecting a similar performance in Q4 [33] Question: What is the current cash position and need for capital? - The company has sufficient cash to operate for several quarters and is looking for opportunities to improve its financial position if necessary [50]

Group 1: RLX Technology Inc - RLX Technology Inc reported quarterly earnings of 3 cents per share on sales of $158.600 million [1] - Shares of RLX Technology rose 6% to $2.47 in pre-market trading following the earnings report [1] Group 2: Other Stocks in Pre-Market Trading - Cidara Therapeutics, Inc. surged 92% to $203.50 after a Schedule 13D Amendment revealed beneficial ownership of 3.37 million shares [4] - Binah Capital Group, Inc. gained 52.2% to $2.17 after posting stronger-than-expected third-quarter results [4] - Expion360 Inc. rose 42.4% to $1.81 following its third-quarter results [4] - Aspire Biopharma Holdings, Inc. surged 31.2% to $0.1380 in pre-market trading [4] - Invivyd, Inc. gained 28.8% to $2.28 after reporting better-than-expected third-quarter financial results [4] - Milestone Scientific Inc. surged 26.3% to $0.4801 after reporting better-than-expected third-quarter sales [4] - Lazydays Holdings, Inc. gained 23.3% to $1.85 after a previous surge [4] - Omeros Corp gained 12.5% to $7.08 following a narrower-than-expected quarterly loss [4] - Nouveau Monde Graphite Inc rose 10% to $3.25 after a decline the previous day [4] Group 3: Declining Stocks in Pre-Market Trading - TSS Inc tumbled 40.2% to $9.10 after reporting a year-over-year decrease in third-quarter results [4] - enVVeno Medical Corp declined 35.8% to $0.42 after an unfavorable FDA appeal decision [4] - Nuvve Holding Corp fell 29.3% to $0.34 after announcing third-quarter results [4] - ESS Tech Inc shares dipped 24.2% to $3.22 after reporting weak quarterly sales [4] - Direct Digital Holdings Inc fell 18.8% to $0.23 after a significant gain the previous day [4] - StubHub Holdings Inc fell 18.8% to $15.28 after worse-than-expected third-quarter EPS results [4] - Mangoceuticals Inc dipped 17.7% to $0.98 after a decline the previous day [4] - Red Cat Holdings Inc dipped 15.1% to $6.57 after worse-than-expected financial results and a lowered FY25 sales guidance [4] - WhiteFiber Inc fell 13.4% to $17.21 after reporting worse-than-expected financial results [4] - Sobr Safe Inc fell 12.4% to $2.21 after a decline the previous day [4]

Core Insights - Milestone Scientific Inc. reported a significant increase in share price, surging 35.67% in after-hours trading to $0.52 following the release of its third-quarter results, which showed lower costs and improved losses [1] Financial Performance - The company reduced its operating expenses by over $500,000 in Q3 compared to the same period last year, contributing to improved margins [2] - Operating loss decreased by 23% to approximately $1.1 million from $1.5 million a year earlier, while net loss narrowed to $1.2 million, or $0.01 per share, compared to $1.5 million, or $0.02 per share, in Q3 2024 [3] - Third-quarter revenue was about $2.4 million, slightly down from $2.5 million in the same quarter last year, with lower domestic dental sales offset by stronger international demand and steady recurring medical revenue [4] - For the first nine months of the year, revenue increased by 5% to $6.9 million from $6.6 million, driven by growth in international dental markets and higher recurring revenue in the medical segment [4] Strategic Developments - The CEO highlighted the company's positive outlook on growing utilization and recurring revenue from CompuFlo disposables, alongside advancements in its reimbursement strategy, which includes recent Medicare payment-rate assignments and expanded commercial coverage [5] Stock Performance - Year-to-date, Milestone Scientific's shares have declined by 59.61%, with stock prices fluctuating between $0.35 and $1.39 over the past year, and a market capitalization of approximately $29.8 million [6]

Revenue Performance - Total product sales for the three months ended September 30, 2025, were approximately $2.36 million, a decrease of about $154,000 or 6% compared to $2.51 million in the same period of 2024[116] - Dental revenue for the three months ended September 30, 2025, was approximately $2.32 million, down $149,212 from $2.47 million in the prior year[115] - International dental revenue decreased to approximately $1.0 million in Q3 2025, compared to $1.2 million in Q3 2024, a reduction of approximately $242,000 or 20%[119] - Revenue from Dental Service Organizations (DSOs), government agencies, and dental schools increased slightly to approximately $83,000 for the three months ended September 30, 2025, compared to $81,000 in the prior-year period[117] - E-commerce dental revenue totaled approximately $1.0 million for the three months ended September 30, 2025, compared to $1.1 million for the same period in 2024, a decrease of approximately $105,000 or 9%[118] - Consolidated revenue for the nine months ended September 30, 2025, was approximately $6.9 million, representing an increase of approximately $300,000, or 5%, compared to $6.6 million in 2024[130] - International revenue for the nine months ended September 30, 2025, was approximately $2.9 million, an increase of approximately $211,000, or 8%, compared to $2.7 million in 2024[133] Profitability and Loss - Gross profit for the three months ended September 30, 2025, was $1.64 million, compared to $1.84 million in the same period of 2024[114] - The net loss for the three months ended September 30, 2025, was $1.15 million, compared to a net loss of $1.46 million in the same period of 2024[114] - The loss from operations for the three months ended September 30, 2025, was approximately $1.1 million, an improvement of approximately $335,000, or 22%, compared to $1.5 million in 2024[128] - The loss from operations for the nine months ended September 30, 2025, was approximately $4.6 million, an improvement of approximately $98,000, or 2%, compared to $4.7 million in 2024[141] Expenses - Operating expenses for the three months ended September 30, 2025, totaled $2.78 million, down from $3.31 million in the prior year[114] - Consolidated selling, general, and administrative (SG&A) expenses for the three months ended September 30, 2025, were approximately $2.7 million, a decrease of approximately $325,000, or 10%, compared to $3.1 million in 2024[124] - Consolidated research and development (R&D) expenses for the three months ended September 30, 2025, were approximately $16,000, representing a decrease of approximately $216,000, or 93%, compared to $232,000 in 2024[126] - Consolidated research and development (R&D) expenses for the nine months ended September 30, 2025, were approximately $437,000, a decrease of approximately $204,000, or 32%, compared to $641,000 in 2024[138] Cash Flow and Financial Position - Net cash provided by financing activities increased by approximately $553,000 for the nine months ended September 30, 2025, compared to the same period in 2024, primarily due to the issuance of $800,000 in convertible notes payable during 2025[146] - As of September 30, 2025, the Company had cash and cash equivalents of approximately $1.3 million and working capital of approximately $3.1 million[149] - Net cash flows used in operating activities were approximately $2.7 million for the nine months ended September 30, 2025, compared to $1.4 million for the same period in 2024[149] Going Concern and Future Outlook - Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of one year from the date these unaudited condensed financial statements are issued[149] - The Company is actively pursuing additional sources of funding through equity and debt financing to support its operating plan[150] - The continuation of operations is dependent upon the Company's ability to raise additional capital and achieve sustained profitability[151] - The Company continues to focus on generating positive cash flow from operations by increasing revenue from its dental business and expanding sales of medical devices and disposables[151] Market Developments - The company has received FDA clearance for the CompuFlo® Epidural Computer Controlled Anesthesia System, expanding its market potential in medical applications[109] - The recent issuance of a CPT code by the American Medical Association enhances reimbursement potential for epidural procedures using the CompuFlo® system, supporting broader adoption in the U.S.[110] - Sales in China for the three months ended September 30, 2025, were approximately $200,000, compared to no sales in the same period of 2024, reflecting successful reestablishment of operations[120] - Revenue from the medical segment totaled approximately $41,000 for the three months ended September 30, 2025, a decrease of approximately $6,000, or 13%, compared to the same period in 2024[121] Consolidated Financial Performance - Consolidated gross profit for the three months ended September 30, 2025, was approximately $1.6 million, representing a decrease of approximately $195,000, or 11%, compared to $1.8 million in 2024[123]

Core Insights - Milestone Scientific Inc. reported continued progress in operational transformation and growth strategy across its dental and medical segments, with a focus on building a leaner organization for sustained growth and improved profitability [1][2]. Financial Performance - For Q3 2025, revenues were approximately $2.4 million, a slight decrease from $2.5 million in Q3 2024, primarily due to lower domestic dental sales, partially offset by higher international dental sales and recurring medical revenue [3]. - Gross profit for Q3 2025 was approximately $1.6 million, or 70% of revenue, compared to $1.8 million, or 73% of revenue, in Q3 2024 [3]. - The operating loss for Q3 2025 was approximately $(1.1) million, an improvement of approximately $0.3 million, or 23%, from $(1.5) million in Q3 2024, attributed to lower selling, general, and administrative expenses [3]. - The net loss for Q3 2025 was approximately $(1.2) million, or $(0.01) per share, compared to a net loss of $(1.5) million, or $(0.02) per share, in Q3 2024 [3]. Year-to-Date Results - For the nine months ended September 30, 2025, revenues were approximately $6.9 million, an increase of approximately $0.3 million, or 5%, from $6.6 million in the same period of 2024, driven by growth in international dental sales and higher recurring revenue from the medical segment [4]. - Gross profit for the nine months ended September 30, 2025, was approximately $4.9 million, or 71% of revenue, consistent with the previous year [4]. - The operating loss for the nine months ended September 30, 2025, was approximately $(4.6) million, slightly improved from $(4.7) million in the same period of 2024 [4]. - The net loss for the nine months ended September 30, 2025, was approximately $(4.6) million, or $(0.06) per share, compared to a net loss of $(2.7) million, or $(0.03) per share, in the same period of 2024 [4]. Cash Position - As of September 30, 2025, the company reported cash and cash equivalents of approximately $1.3 million and working capital of approximately $3.1 million [5]. Strategic Initiatives - The company is expanding its direct sales programs in North America and securing new international registrations for its STA® Single Tooth Anesthesia System, while enhancing its omnichannel digital marketing strategy [2]. - There is growing utilization and recurring revenue from CompuFlo® disposables, with increasing interest from hospitals and international distributors [2]. - The company is advancing its reimbursement strategy for CompuFlo®, focusing on securing Medicare payment-rate assignments and expanding commercial coverage, which are seen as key enablers for broader adoption [2].

Core Viewpoint - Milestone Scientific Inc. will host a conference call to discuss its third-quarter financial results and corporate developments on November 14, 2025 [1] Company Overview - Milestone Scientific Inc. is a technology-focused medical research and development company that specializes in innovative injection technologies for medical, dental, and cosmetic applications [4] - The company’s computer-controlled systems aim to enhance injection precision, efficiency, and overall patient comfort and safety [4] - Milestone Scientific's proprietary DPS Dynamic Pressure Sensing Technology is designed to regulate flow rate and monitor pressure during subcutaneous drug delivery, including local anesthetics [4]

Core Insights - Milestone Scientific Inc. is undergoing a transformation aimed at strengthening its dental and medical businesses, reducing operating expenses, and positioning the company for accelerated growth and improved financial performance [1] Business Strategy - The new CEO, Eric Hines, has conducted a comprehensive review of operations and implemented strategic actions to accelerate growth, strengthen competitive position, and improve operating efficiency [2] - In the dental segment, the company is expanding North American sales programs, focusing on direct sales, enhancing omnichannel digital marketing, and securing new international registrations for the STA® Single Tooth Anesthesia System [2] - A similar strategy will be applied to the medical segment, including a guided relaunch of CompuFlo® and investment in market analysis and reimbursement strategies to maximize its commercial potential [2] Financial Performance - In the third quarter, the company reduced operating expenses by approximately 20% compared to the same period in 2024 while achieving modest revenue growth and an increase in recurring revenue from CompuFlo disposables [3] - There is strong international interest in CompuFlo, indicating potential for future growth [3] Future Outlook - The company is committed to advancing its innovative technology, expanding market presence, and executing on new products and partnerships [3] - The steps being taken are expected to provide a strong foundation for sustained growth and profitability [3]